In AD patients, yearly average increases in TSPO binding that ranged from 2.5 to 7.7% were shown using [11C]PBR28 (Kreisl et al., 2016), whilst for [18F]DPA‐714 an elevated annual change of 13.2% in tracer binding was displayed (Hamelin et al., 2018). This evidence concerns the gene TSPO and Alzheimer disease.